New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2012
16:19 EDTJPM, JNJ, RMBS, LCC, AAMRQ, CASY, REGNOn The Fly: Closing Wrap
Stocks on Wall Street were lower following disappointing U.S. economic data. Stock futures were lower in premarket trading but tumbled following disappointing retail sales figures for the month of May. The market opened lower but soon found a level from where it started to build. The averages crossed into positive territory could not gain any upside momentum. The middle of the day was characterized by the market drifting back and forth across the baseline as it underwent a period of consolidation, in contrast to the previous two days, which were marked by big swings in the averages. In the last hour of trading the market fell sharply to wind up down for the day… ECONOMIC EVENTS: In the U.S., retail sales slipped 0.2%, which was in line with expectations, but if auto and gasoline data are excluded the "core" reading showed a decline of 0.1%, versus expectations of an increase of 0.4%. Producer prices in the month of May declined 1.0%, versus expectations of a decline of 0.6%, but if food and energy are removed the reading was up 0.2%, which was in line with forecasts. Business inventories grew 0.4% in April, versus expectations for an increase of 0.3%. In Europe, Italy’s national borrowing rate skyrocketed to its highest level since December, as investors became jittery about contagion from Spain’s request for external assistance… COMPANY NEWS: JPMorgan's (JPM) CEO Jamie Dimon testified in front of the Senate Banking Committee, saying that he expects the current quarter to be "solidly profitable" in spite of the "London Whale's" losses and that clawbacks of executive pay are likely following the bank's review of the incident. Dimon argued that complex institutions are necessary to meet the needs of business and that there are many advantages and only some negatives to big banks. Following his testimony JPMorgan’s shares rose 53c, or 1.57%, to $34.30... Johnson & Johnson (JNJ) shares rose $1.37, or 2.17%, to $64.45, after JPMorgan, Jefferies and Raymond James all upgraded the stock this morning. Last night, the pharmaceutical giant confirmed it has received U.S. regulatory clearance for its proposed acquisition of Synthes and announced a new accelerated share repurchase agreement... MAJOR MOVERS: Among the notable gainers were Rambus (RMBS), up 44c, or 9.16%, to $5.30, after being initiated with a Buy rating and $10 price target at Sidoti, and U.S. Airways (LCC), up 54c, or 4.72%, to $11.97, after multiple sources indicated that the company plans to file paperwork with U.S. antitrust regulators as soon as next month for a proposed merger with AMR (AAMRQ). Noteworthy losers included Casey’s General Stores (CASY), down $7.73, or 12.90%, to $52.18, after missing on Q4 EPS, and Regeneron (REGN), down $15.97, or 12.49%, to $111.88, after competitor Ophthotech announced positive data from a clinical trial… INDICES: The Dow lost 77.42, or 0.62%, to 12,496.38; the Nasdaq fell 24.46, or 0.86%, to 2,818.61; and the S&P 500 dropped 9.30, or 0.70%, to 1,314.88.
News For JPM;JNJ;RMBS;LCC;AAMRQ;CASY;REGN From The Last 14 Days
Check below for free stories on JPM;JNJ;RMBS;LCC;AAMRQ;CASY;REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 15, 2014
07:49 EDTJNJJohnson & Johnson reports Q2 Worldwide Pharmaceutical sales of $8.5B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson raises FY14 EPS to $5.85-$5.92 from $5.75-$5.85
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales up 14.9% to $9.13B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 EPS excluding items $1.66, consensus $1.55
Subscribe for More Information
07:23 EDTJPMFortune to hold a conference
Subscribe for More Information
07:08 EDTJPMJPMorgan CEO says saw encouraging signs toward end of Q2
Subscribe for More Information
07:06 EDTJPMJPMorgan reports Q2 Basel III Common Equity Tier 1 ratio 9.8%
Reports Common Equity Tier 1 of $161B, or ratio of 9.8%. Reports Firm Supplementary Leverage Ratio of 5.4%. Reports "core loans" up 8% compared with the prior year. Consumer & Community Banking: average Consumer & Business Banking deposits up 9%; credit card sales volume up 12%; record client investment assets up 19%; record Business Banking loan originations up 46% Corporate & Investment Bank: maintained #1 ranking for Global Investment Banking fees with 8.2% wallet share YTD; assets under custody up 14%. Commercial Banking: period-end loan balances up 9%, driven by 14% growth in Commercial Real Estate; gross investment banking revenue with Commercial Banking clients up 25%. Asset Management: twenty-first consecutive quarter of positive net long-term client flows; record client assets up 15%; record loan balances up 17%.
07:05 EDTJPMJPMorgan reports headcount down 8,871 to 245,192
Subscribe for More Information
07:04 EDTJPMJPMorgan reports Q2 provision for credit losses $692M
Subscribe for More Information
07:02 EDTJPMJPMorgan says Q2 results include $500M after-tax, or 13c, legal expense
Subscribe for More Information
07:01 EDTJPMJPMorgan reports Q2 adjusted EPS $1.46, consensus $1.29
Subscribe for More Information
06:19 EDTJPMJPMorgan reports June net charge losses 2.84% vs. 3.05% last month
Subscribe for More Information
July 14, 2014
15:24 EDTJNJ, JPMNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:40 EDTJPMJPMorgan July 56.5 straddle priced for 2.2% move into Q2
Subscribe for More Information
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
09:14 EDTRMBSSemiconductor top picks at Topeka
Topeka's anticipates strong unit growth in the smartphone, tablet and wearable end markets and recommends exposure to large/mid cap growth names Intel (INTC), Skyworks (SWKS), Atmel and (ATML), small cap growth name, Rambus (RMBS), and value names Freescale (FSL), Spansion (CODE) and Silicon Motion (SIMO).
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
08:01 EDTJPMJP Morgan July volatility increases into Q2 and outlook
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use